Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewEmerging treatment options for nasopharyngeal carcinomaTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaRole of chemotherapy in nasopharyngeal carcinomaOccipital lymph node metastasis from nasopharyngeal carcinoma: a special case report and literature reviewMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Endoscope-guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma.Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results.Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapyModeling nasopharyngeal carcinoma in three dimensionsSuppression Of β-catenin Nuclear Translocation By CGP57380 Decelerates Poor Progression And Potentiates Radiation-Induced Apoptosis in Nasopharyngeal Carcinoma.Optimal management of a patient with recurrent nasopharyngeal carcinoma.Parametric contrast-enhanced ultrasound as an early predictor of radiation-based therapeutic response for lymph node metastases of nasopharyngeal carcinoma.Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes.Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit?Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation.Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cellsIdentification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinomaPrognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases.Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinomaTherapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.Current and emerging treatment options for nasopharyngeal carcinoma.Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.Cetuximab in the treatment of head and neck cancer.Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of SlugThe emerging role of cetuximab in head and neck cancer: a 2007 perspective.Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer.Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy.Nasopharyngeal carcinoma: alternative treatment options after disease progression.
P2860
Q21198850-3B897976-4F5B-4C09-A05C-6E9788916540Q26995560-5AED6F5A-4354-4F96-B73E-5330EB812831Q27016002-AB85AC0A-DA6A-490B-85D7-6FE2F4D245E8Q27022454-C0D05F8A-D32A-42DA-BDE7-16D43D13780BQ28078860-53B933B9-7B89-4685-84C3-017AAB16D6F3Q30846827-554DCE39-38B5-4179-8402-D7E89C72CF2BQ31152476-2B110048-64CE-47A5-96CD-A6116DA638B5Q33378256-2315B6DD-7553-437C-8DE2-A9D061755202Q33383131-B31B88BB-CE79-4058-B2D5-43E41D563540Q33410822-68856E07-585C-474C-86F3-1D53D112C669Q33579689-E6AAEBCA-BDD5-44C1-A3FF-9BA9C8886F07Q33599243-2FE38B9F-1956-427F-B6A9-AA50D595972CQ33836444-EF3963FB-12D5-45FB-A145-79DD5FC2067FQ33898262-65535EED-2355-4B29-8A1B-0DD676CF81F7Q33933009-9AD49EEB-D07B-47DB-B7F2-A746772F0B22Q33994022-4EAB6888-5B80-43B6-B247-3CA4143F9488Q34001937-02136D6A-2EB4-4125-AF67-FFE127194805Q34242449-9F454B6B-70FB-4DC4-A93F-3AB39D1D6DA9Q34488787-C6DB2CB7-4D6A-4674-8103-589445D8F8BFQ34771143-A9CF7F63-14EA-45AF-95CC-B5EA54B5A48FQ35117590-B772FDBA-8627-4F46-B60E-078E9F47CA5FQ35480110-679802DE-ABB6-4CF0-8FBB-A680848E7FFEQ35552076-2BAB7418-C989-4E63-B97C-668D4E6713C8Q35860283-AD714DCB-CC61-4261-A53C-134C9B7B74E5Q36014988-6B32FAB8-FBA3-4CFA-BDC3-DACF5024BE32Q36241068-566B99FC-0AC8-420E-977B-A493B72644BDQ36359374-D6565EA3-ACB5-4E26-80C5-D36438025504Q36407458-CAC2A979-E757-4386-B0C8-EAE2D521F2F2Q36545328-E3E82B24-5613-4ACC-BFA2-52CDDE14304BQ36613969-4CF0F7A0-4D88-410F-BF54-2BFB648A03D2Q36629614-E3F6959B-E3BF-427F-805A-72A185DC200BQ36668224-2EAEA009-E494-4DA4-944D-5350E1D192C5Q36707878-67DE5411-F2BE-4968-BD3C-770060B078ACQ37052756-6A766D0E-1DB6-4571-97B8-D00CEF18354DQ37171008-B185D468-B1CA-4F50-B521-D31F9209673CQ37230165-4C984941-0E62-4F5F-A78A-9C65B9F1FAB6Q37248002-BA332191-6385-4893-9FCA-D077C0A65A29Q37282841-59339D3B-A7C8-40E5-A238-89C9AEDAC228Q37520428-EE545635-0CAB-4E9F-96CD-4B2BDE585414Q37705415-BA112FED-8938-45C5-A427-697735D3EBB6
P2860
Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Multicenter, phase II study of ...... atic nasopharyngeal carcinoma.
@en
Multicenter, phase II study of ...... atic nasopharyngeal carcinoma.
@nl
type
label
Multicenter, phase II study of ...... atic nasopharyngeal carcinoma.
@en
Multicenter, phase II study of ...... atic nasopharyngeal carcinoma.
@nl
prefLabel
Multicenter, phase II study of ...... atic nasopharyngeal carcinoma.
@en
Multicenter, phase II study of ...... atic nasopharyngeal carcinoma.
@nl
P2093
P356
P1476
Multicenter, phase II study of ...... tatic nasopharyngeal carcinoma
@en
P2093
Alex Y Chang
Boon C Goh
Edwin P Hui
Jacqueline Whang-Peng
Matthias Mueser
Michael J Millward
Mow-Ming Hsu
Nadia Amellal
Ruey-Long Hong
P304
P356
10.1200/JCO.2005.02.147
P407
P577
2005-04-04T00:00:00Z